Citations

Clear

941 citation(s) found for "Tefferi, A".

Phase II trial of panobinostat, an oral pan‐deacetylase inhibitor in patients with primary myelofibrosis, post–essential thrombocythaemia, and post–polycythaemia vera myelofibrosis
Tefferi, Ayalew , Paley, Carole, Wadleigh, Martha , Ritchie, Ellen K. , Snyder, David S., Begna, Kebede H. , Ganguly, Siddhartha , Ondovik, Michael S., Rine, Jessica, Bhalla, Kapil N. , DeAngelo, Daniel J. , Mesa, Ruben A. , Fiskus, Warren C.

Mayo Clinic

British Journal of Haematology | May 23, 2013 | Volume: 162 | Issue: 3 | Pages: 326-335

10.1111/bjh.12384 | PMID 23701016 Get It

SummaryMyelofibrosis (MF) is a Philadelphia chromosome–negative stem cell myeloproliferative neoplasm (MPN) associated with cytopenias, splenomegaly, constitutional symptoms, and poor prognosis. MF patients commonly express JAK2 V617F mutation and activation of Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signalling. Agents targeting the JAK/STAT pathway have demonstrated efficacy in patients with MF. This study evaluated panobinostat, a pan‐deacetylase inhibitor that depletes JAK2 V617F levels and JAK/STAT signalling in MPN cells, in patients with primary MF, post–essential thrombocythaemia MF, and post–polycythaemia vera MF. Patients received panobinostat 40 mg administered three times per week. Dose reductions were permitted for toxicities. The primary endpoint was response rate at 6 months using International Working Group for Myelofibrosis Research and Treatment (IWG‐MRT) consensus criteria. Analyses of peripheral blood cells from treated patients revealed that panobinostat inhibited JAK/STAT signalling, decreased inflammatory cytokine levels, and decreased JAK2 V617F allelic burden. However, panobinostat was poorly tolerated at the dose and schedule evaluated, and only 16 of 35 patients completed ≥2 cycles of treatment. One patient (3%) achieved an IWG‐MRT response. Common adverse events were thrombocytopenia (71·4%) and diarrhoea (80·0%). Although molecular correlative analyses suggested that panobinostat inhibits key intracellular targets, limited clinical activity was observed because of poor tolerance.
Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk‐stratification, and management
Tefferi, Ayalew

Mayo Clinic

American Journal of Hematology | May 22, 2013 | Volume: 88 | Issue: 6 | Pages: 507-516

10.1002/ajh.23417 | PMID 23695894 Get It

Disease OverviewPolycythemia Vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms (MPN) primarily characterized by erythrocytosis and thrombocytosis, respectively. Other disease features include leukocytosis, splenomegaly, thrombohemorrhagic complications, vasomotor disturbances, pruritus and a small risk of disease progression into acute myeloid leukemia or myelofibrosis.DiagnosisAlmost all patients with PV harbor aJAK2mutation. When PV is suspected, the presence of aJAK2mutation highly suggests the diagnosis and its absence, combined with normal or increased serum erythropoietin level, excludes the diagnosis. Differential diagnosis of ET should include reactive thrombocytosis, chronic myeloid leukemia, prefibrotic myelofibrosis and RARS‐T (refractory anemia with ring sideroblasts associated with marked thrombocytosis). AJAK2mutation is found in 50–70% of patients with ET, myelofibrosis or RARS‐T and is capable of distinguishing reactive from clonal thrombocytosis.Risk StratificationCurrent risk stratification in PV and ET is designed to estimate the likelihood of thrombotic complications: high‐risk is defined by the presence of age >60 years or presence of thrombosis history; low‐risk is defined by the absence of both of these two risk factors. Recent data considersJAK2V617F and cardiovascular (CV) risk factors as additional risk factors for thrombosis. Presence of extreme thrombocytosis (platelet count >1,000 × 109/L) might be associated with acquired von Willebrand syndrome (AvWS) and, therefore, risk of bleeding. Risk factors for shortened survival in both PV and ET include advanced age, leukocytosis, and history of thrombosis.Risk‐Adapted TherapySurvival is near‐normal in ET and reasonably long in PV. The 10‐year risk of leukemic/fibrotic transformation is <1%/1% in ET and <3%/10% in PV. In contrast, the risk of thrombosis exceeds 20%. The main goal of therapy is therefore to prevent thrombohemorrhagic complications. In low risk patients, this is effectively and safely accomplished by the use of low‐dose aspirin in both PV and ET and phlebotomy (hematocrit target of <45%) in PV. In high risk patients, treatment with hydroxyurea is additionally recommended, although not mandated in older patients withoutJAK2V617F or CV risk factors. Treatment with busulfan or interferon‐α is usually effective in hydroxyurea failures. Screening for clinically significant AvWS is recommended before administrating aspirin in the presence of extreme thrombocytosis. Am. J. Hematol. 88:508–516, 2013. © 2013 Wiley Periodicals, Inc.
Evaluation of revised IPSS cytogenetic risk stratification and prognostic impact of monosomal karyotype in 783 patients with primary myelodysplastic syndromes
Gangat, Naseema , Patnaik, Mrinal M. , Begna, Kebede H. , Kourelis, Taxiarchis , Knudson, Ryan A., Ketterling, Rhett P. , Hodnefield, Janice M., Hanson, Curtis A. , Pardanani, Animesh , Tefferi, Ayalew , Ketterling, Rhett P

Mayo Clinic

American Journal of Hematology | May 20, 2013 | Volume: 88 | Issue: 8 | Pages: 690-693

10.1002/ajh.23477 | PMID 23686868 Get It

Cytogenetic classification by the revised international prognostic scoring system (IPSS‐R) and the prognostic value of monosomal karyotype (MK) were assessed in 783 patients with primary myelodysplastic syndromes (MDS). At 22 months median follow‐up, 562 (72%) deaths were recorded. Percentages of patients with IPSS‐R “very good,” “good,” “intermediate,” “poor,” and “very poor” cytogenetic categories was 5, 63, 18, 4, and 10%, respectively. The corresponding median survivals were 21, 40, 24, 18, and 6.5 months and the inter‐group differences (good vs. very good/intermediate/poor vs. very poor; P < 0.01) or similarities (very good vs. intermediate vs. poor; P = 0.79) were not significantly modified in multivariable analysis. Results were similar when analysis was restricted to 602 patients managed by supportive care. MK adversely affected survival in both poor and very poor karyotype groups (P < 0.01). In conclusion, we were unable to confirm the prognostic superiority of IPSS‐R‐very good karyotype or prognostically distinguish between very good, intermediate and poor karyotypes. Furthermore, we show additional prognostic information from MK in poor/very poor karyotype. Am. J. Hematol. 88:690–693, 2013. © 2013 Wiley Periodicals, Inc.
Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project
Harrison, Claire , Kiladjian, Jean‐Jacques , Lengfelder, Eva , Passamonti, Francesco , Besses, Carlos , Gisslinger, Heinz , Samuelsson, Jan , Verstovšek, Srđan , Pardanani, Animesh , Cervantes, Francisco , Tefferi, Ayalew , Barbui, Tiziano , Barosi, Giovanni , Mesa, Ruben A. , Finazzi, Guido , McMullin, Mary Frances , Vannucchi, Alessandro M. , Hoffman, Ronald , Verstovsek, Srdan , Kiladjian, Jean-Jacques , Passamonti, Francesco

Mayo Clinic

Blood | April 16, 2013 | Volume: 121 | Issue: 23 | Pages: 4778-4781

10.1182/blood-2013-01-478891 | PMID 23591792 Get It

Key Points Evidence exists that ELN criteria for response in ET and PV issued in 2009 do not provide relevant measures of benefit for patients. Revised recommendations for assessing response are provided.
Nilotinib treatment‐associated cerebrovascular disease and stroke
Zalewski, Nicholas L. , Hoffman, E. Matthew , Tefferi, Ayalew , Flemming, Kelly D. , Coon, Elizabeth A. , Flemming, Kelly D

Mayo Clinic

American Journal of Hematology | March 23, 2013 | Volume: 88 | Issue: 6 | Pages: 534-535

10.1002/ajh.23442 | PMID 23526495 Get It

Prognostic impact of RAS mutations in patients with myelodysplastic syndrome
Al‐Kali, Aref , Luthra, Raja, Bueso‐Ramos, Carlos E. , Kadia, Tapan M. , Faderl, Stefan, Cortes, Jörge E. , Tefferi, Ayalew , Kantarjian, Hagop M. , Garcia‐Manero, Guillermo , Quintás‐Cardama, Alfonso , Pierce, Sherry A. , Borthakur, Gautam , Estrov, Zeev E. , Jabbour, Elias , Ravandi, Farhad , Cortes, Jorge , Kantarjian, Hagop

Mayo Clinic

American Journal of Hematology | February 8, 2013 | Volume: 88 | Issue: 5 | Pages: 365-369

10.1002/ajh.23410 | PMID 23512829 Get It

RAS is an oncogene frequently mutated in human cancer. RAS mutations have been reported in 10–15% of cases of acute myeloid leukemia (AML) but they appear to be less frequent among patients with myelodysplastic syndrome (MDS). The impact of RAS mutations in patients with MDS is unclear. We conducted a retrospective study in 1,067 patients with newly diagnosed MDS for whom RAS mutational analysis was available. Overall, 4% of patients carried mutant RAS alleles. Notably, FLT3 mutations, which were found in 2% of patients, were mutually exclusive with RAS mutations. Patients with RAS mutations had a higher white blood cell count as well as bone marrow blasts compared with patients carrying wild‐type RAS. However, no differences were observed between both groups regarding the risk of AML transformation (9% vs. 7%) and overall survival (395 days vs. 500 days, P = 0.057). In summary, RAS mutations are infrequent in patients with MDS and do not appear to negatively impact their outcome. Am. J. Hematol. 88:365–369, 2013. © 2013 Wiley Periodicals, Inc.
Associations and prognostic interactions between circulating levels of hepcidin, ferritin and inflammatory cytokines in primary myelofibrosis
Pardanani, Animesh , Finke, Christy M. , Abdelrahman, Ramy A., Tefferi, Ayalew , Lasho, Terra L.

Mayo Clinic

American Journal of Hematology | February 6, 2013 | Volume: 88 | Issue: 4 | Pages: 312-316

10.1002/ajh.23406 | PMID 23450619 Get It

Iron homeostasis is dysregulated in primary myelofibrosis (PMF), given the high prevalence of anemia, need for red blood cell (RBC) transfusions, and disease‐associated inflammatory state. We measured plasma hepcidin levels in 203 consecutive PMF patients at the time of first referral; hepcidin levels were significantly higher as compared to healthy controls ( P < 0.0001), and were correlated with hemoglobin of <10 g/dL, RBC transfusion requirement, serum ferritin of >500 µg/L, higher dynamic international prognostic scoring system (DIPSS)‐plus risk category, the presence of circulating blasts, age of >65 years, and leukocyte count of <4 × 10 9 /L. Increased hepcidin levels predicted for inferior survival independent of six out of the eight DIPSS‐plus prognostic parameters (hazard ratio [HR] = 1.8; P = 0.02), but not when RBC transfusion requirement, hemoglobin of <10 g/dL, or increased serum ferritin were included in the Cox model. Multivariable analysis that considered the four overlapping prognostic variables revealed that increased hepcidin (HR = 1.9; P = 0.03) and increased ferritin (HR = 2.3; P = 0.04), but not hemoglobin of <10 g/dL or RBC transfusion requirement, independently retained their significance for predicting survival. Accordingly, increased levels of both hepcidin and serum ferritin (seen in 29% of patients) predicted inferior survival independent of DIPSS‐plus or increased inflammatory cytokine levels (HR = 2.4; P = 0.002), and could be considered in future prognostic models for PMF. Am. J. Hematol. 88:312–316, 2013. © 2013 Wiley Periodicals, Inc.
Primary myelofibrosis: 2013 update on diagnosis, risk‐stratification, and management
Tefferi, Ayalew

Mayo Clinic

American Journal of Hematology | January 24, 2013 | Volume: 88 | Issue: 2 | Pages: 141-150

10.1002/ajh.23384 | PMID 23349007 Get It

Disease overviewPrimary myelofibrosis (PMF) is a myeloproliferative neoplasm characterized by stem cell‐derived clonal myeloproliferation, abnormal cytokine expression, bone marrow fibrosis, anemia, splenomegaly, extramedullary hematopoiesis (EMH), constitutional symptoms, cachexia, leukemic progression, and shortened survival.DiagnosisDiagnosis is based on bone marrow morphology. The presence of fibrosis,JAK2/MPLmutation, or +9/13q− cytogenetic abnormality is supportive but not essential for diagnosis. PrefibroticPMFmimics essential thrombocythemia in its presentation and the distinction is prognostically relevant. Differential diagnosis of myelofibrosis should include chronic myeloid leukemia, myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia.Risk stratificationThe Dynamic International Prognostic Scoring System‐plus (DIPSS‐plus) prognostic model forPMFcan be applied at any point during the disease course and uses eight independent predictors of inferior survival: age >65 years, hemoglobin <10 g/dL, leukocytes >25 × 109/L, circulating blasts ≥1%, constitutional symptoms, red cell transfusion dependency, platelet count <100 × 109/L, and unfavorable karyotype (i.e., complex karyotype or sole or two abnormalities that include +8, −7/7q−, i(17q), inv(3), −5/5q−, 12p−, or 11q23 rearrangement). The presence of 0, 1, “2 or 3,” and ≥4 adverse factors defines low, intermediate‐1, intermediate‐2, and high‐risk disease with median survivals of approximately 15.4, 6.5, 2.9, and 1.3 years, respectively. A >80% two‐year mortality is predicted by monosomal karyotype, inv(3)/i(17q) abnormalities, or any two of circulating blasts >9%, leukocytes ≥40 × 109/L or other unfavorable karyotype. Most recently, mutations involvingASXL1,SRSF2,EZH2, andIDH1/2or increased plasma IL‐2R, IL‐8, or serum‐free light chain levels have been shown to adversely affect survival.Risk‐adapted therapyObservation alone is adequate for asymptomatic low/intermediate‐1 risk disease. Allogeneic stem cell transplantation (ASCT) is often considered for high risk disease. Conventional or experimental drug therapy is reasonable for symptomatic intermediate‐1 or intermediate‐2 risk disease; however,ASCTis an acceptable treatment option for such patients in the presence ofASXL1or other prognostically adverse mutations. Splenectomy and low‐dose radiotherapy are used for drug‐refractory splenomegaly. Radiotherapy is also used for the treatment of non‐hepatosplenicEMH,PMF‐associated pulmonary hypertension, and extremity bone pain. Am. J. Hematol. 88:141–150, 2013. © 2012 Wiley Periodicals, Inc.
International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis
Pardanani, Animesh , Akin, Cem , Reiter, Andreas , George, Tracy I. , Hermine, Olivier , Kluin‐Nelemans, Hanneke C. , Hartmann, Karin , Sperr, Wolfgang R. , Schwartz, Lawrence B. , Arock, Michel , Sotlar, Karl , Horny, Hans-Peter, Metcalfe, Dean D. , Escribano, Luís, Verstovšek, Srđan , Tefferi, Ayalew , Valent, Peter , Gotlib, Jason , Brockow, Knut , Órfão, Alberto , DeAngelo, Daniel J. , Verstovsek, Srdan , George, Tracy I , Sperr, Wolfgang , Valent, Peter , Hermine, Olivier , Akin, Cem , Arock, Michel , Kluin-Nelemans, Hanneke C

Mayo Clinic

Blood | January 17, 2013 | Volume: 121 | Issue: 13 | Pages: 2393-2401

10.1182/blood-2012-09-458521 | PMID 23325841 Get It

Abstract Systemic mastocytosis (SM) is characterized by accumulation of neoplastic mast cells and is classified into indolent and aggressive forms. The latter include aggressive SM (ASM), mast cell leukemia (MCL), and SM associated with a myeloid neoplasm wherein 1 or both disease compartments exhibit advanced features. These variants, henceforth collectively referred to as advanced SM for the purposes of this report, are typically characterized by organ damage and shortened survival duration. In contrast to indolent SM, in which symptoms are usually managed by noncytotoxic antimediator therapy, cytoreduction is usually necessary for disease control in advanced SM. Unfortunately, current drug treatment of these patients rarely results in complete clinical and histopathologic remissions or improved survival time. Previously defined response criteria were adapted to the heterogeneous presentations of advanced SM and the limited effects of available drugs. However, recent advances in understanding the molecular pathogenesis of SM and the corresponding prospect in targeted therapy make it a priority to modify these criteria. Our current study is the product of an international group of experts and summarizes the challenges in accomplishing this task and forwards a new proposal for response criteria, which builds on prior proposals and should facilitate response evaluation in clinical trials.
Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: Prevalence, clinical correlates, and prognostic relevance
Patnaik, Mrinal M. , Finke, Christy M. , Hanson, Curtis A. , Hodnefield, Janice M., Knudson, Ryan A., Ketterling, Rhett P. , Pardanani, Animesh , Tefferi, Ayalew , Lasho, Terra L. , Ketterling, Rhett P

Mayo Clinic

American Journal of Hematology | December 3, 2012 | Volume: 88 | Issue: 3 | Pages: 201-206

10.1002/ajh.23373 | PMID 23335386 Get It

SRSF2, SF3B1, and U2AF35 (U2AF1) are the three most frequent genes involved with spliceosome mutations in myeloid malignancies. SF3B1 mutations are most frequent (~80%) in myelodysplastic syndromes (MDS) with ring sideroblasts (RS) but lack prognostic relevance. SRSF2 mutations are associated with shortened overall (OS) and leukemia‐free survival (LFS) in both MDS and myelofibrosis. In this study of 226 patients with chronic myelomonocytic leukemia (CMML), mutational frequencies were 40% for SRSF2 (all affecting P95), 6% for SF3B1 (primarily K700E) and 9% for U2AF35 (mostly S34F and Q157P/R). These mutations were mutually exclusive and 54% of the patients displayed at least one mutation. The three mutation groups were phenotypically similar, with the exception of higher RS% (P < 0.0001) in patients with SF3B1 mutations. At a median follow‐up of 15 months, 176 (78%) deaths and 32 (14%) leukemic transformations were documented. OS (median survivals of 17, 16, 17, and 20 months; P = 0.48) and LFS (leukemic transformation rates of 17, 13, 15, and 5%; P = 0.63) were similar among patients with none of the three mutations, SRSF2, SF3B1, or U2AF35 mutations, respectively. We conclude that SRSF2 is the most frequently mutated spliceosome gene in CMML but neither it nor SF3B1 or U2AF35 mutations are prognostically relevant. Am. J. Hematol. 88:201–206, 2013. © 2012 Wiley Periodicals, Inc.